Breadcrumb

Breadcrumbs

Press Releases

Search Results

Back to Press Releases
Showing 31 - 35 of 35 results.

You searched for : June 2019 to June 2020.

FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGC ...

FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating Tumor Download the PDF version of Article August 02, 2019 TURALIO is...

Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Rela ...

Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML Download the PDF version of Article June 21, 2019 Tokyo and Basking...

Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory <i>F ...

Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory FLT3-ITD AML Download the PDF version of Article June 18, 2019 VANFLYTA® (quizartinib) is a FLT3...

Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with N ...

Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting Download the PDF version of Article June 02,...

Daiichi Sankyo’s Pexidartinib Demonstrated Further Improvement with Continued Treatment of Tenosyno ...

Daiichi Sankyo’s Pexidartinib Demonstrated Further Improvement with Continued Treatment of Tenosynovial Giant Cell Tumor Patients in New Long-Term Analysis Presented at 2019 ASCO Annual Meeting...

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...